DocGo Wins 'Compliance Management Innovation Award' in 2025 MedTech Breakthrough Awards Program
NEW YORK--(BUSINESS WIRE)-- DocGo Inc. (Nasdaq: DCGO) ('DocGo'), a leading provider of technology-enabled mobile health services, today announced that it has been selected as winner of the 'Compliance Management Innovation Award' in the 9 th annual MedTech Breakthrough Awards program conducted by MedTech Breakthrough, an independent market intelligence organization that recognizes the top companies, technologies and products in the global digital health and medical technology market.
DocGo's breakthrough Compliance Program excels at adapting to the organization's dynamic environment and consistently updating its strategies to address emerging risks and technologies. The program's approach focuses on managing ethics, compliance, and risk management to strengthen corporate culture, drive results, and promote transparency and accountability within the healthcare industry.
DocGo's Compliance Program ensures alignment with industry standards and federal and state regulations, even as the organization scales rapidly and introduces innovative solutions to the healthcare industry. The program's annual compliance survey, a key component, provides employees with an additional confidential channel to report concerns and share feedback.
'Our Compliance Program has been an essential component in the success of our organization, and is built on the foundation of organizational excellence. Along with transparency and ethical practices, our approach remains focused on fostering a culture of trust,' said Stephen Sugrue, DocGo's Chief Compliance Officer. 'We're grateful to MedTech Breakthrough for this recognition, and we remain committed to delivering high quality, highly accessible healthcare to all, and through our meticulously crafted Compliance Program, to do so ethically.'
The MedTech Breakthrough Awards program celebrates excellence and innovation in the health and medical technology industry, recognizing the companies, products, and solutions driving meaningful progress and improving patient care. Spanning a wide range of categories—including Telehealth, Clinical Administration, Patient Engagement, Electronic Health Records (EHR), Virtual Care, Medical Devices, Medical Data & Privacy, and beyond—the awards highlight the groundbreaking work that is transforming the healthcare landscape.
This year's program saw a record-breaking number of nominations from leading companies and startups across more than 18 countries, showcasing the global impact and momentum of the digital healthcare industry today.
'DocGo's approach to compliance offers innovative strategies to consistently build a strong foundation. Healthcare organizations need to implement and streamline policies and procedures that address emerging issues and ensure compliance with regulatory standards. From patient safety to care quality, to employee satisfaction, the right policies build trust and reputation,' said Steve Johansson, managing director, MedTech Breakthrough. 'DocGo's Compliance Program has all the hallmarks of a well-designed program with ample resources, empowerment, and the evidence of working incredibly well in practice. We're thrilled to award them our 2025 'Compliance Management Innovation Award!''
By incorporating the Department of Justice (DOJ) 2024 Evaluation of Corporate Compliance Programs, DocGo's program has been able to further improve its effectiveness strategies. This guidance has been the model framework in building the 2025 Compliance & Audit Work Plan, a valuable resource that assesses the program based on the DOJ's risk strategy initiatives. The work plan has been enhanced with various risk assessments conducted by key stakeholders, as well as incorporating and handling risks with new and emerging technology, and streamlining cybersecurity procedures to improve HIPAA privacy objectives.
About DocGo
DocGo is leading the proactive healthcare revolution with an innovative care delivery platform that includes mobile health services, remote patient monitoring and medical transport solutions. DocGo is helping to reshape the traditional four-wall healthcare system by providing high quality, highly accessible care to patients where and when they need it. DocGo's proprietary technology and relationships with a dedicated field staff of certified health professionals elevate the quality of patient care and drive business efficiencies for facilities, hospital networks and health insurance providers. With Mobile Health, DocGo empowers the full promise and potential of telehealth by facilitating healthcare treatment, in tandem with a remote physician, in the comfort of a patient's home or workplace. Together with DocGo's integrated Ambulnz medical transport services, DocGo is bridging the gap between physical and virtual care. For more information, please visit www.docgo.com. To get an inside look on how the proactive healthcare revolution is helping transform healthcare by reducing costs, increasing efficiency and improving outcomes, visit www.proactivecarenow.com.
About MedTech Breakthrough
Part of Tech Breakthrough, a leading market intelligence and recognition platform for global technology innovation and leadership, the MedTech Breakthrough Awards program is devoted to honoring excellence and innovation in medical & health technology companies, products, services and people. The MedTech Breakthrough Awards provide a platform for public recognition around the achievements of breakthrough healthcare and medical companies and products in categories that include Patient Experience & Engagement, Health & Fitness, Medical Devices, Clinical Administration, Connected Healthcare, Medical Data, Healthcare Cybersecurity and more. For more information visit MedTechBreakthrough.com.
Tech Breakthrough LLC does not endorse any vendor, product or service depicted in our recognition programs, and does not advise technology users to select only those vendors with award designations. Tech Breakthrough LLC recognition consists of the opinions of the Tech Breakthrough LLC organization and should not be construed as statements of fact. Tech Breakthrough LLC disclaims all warranties, expressed or implied, with respect to this recognition program, including any warranties of merchantability or fitness for a particular purpose.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
35 minutes ago
- Yahoo
The Tesla share price could skyrocket next week!
The Tesla (NASDAQ:TSLA) share price is quite frankly hard to keep track of. One moment its down near $220, the next it's pushing towards $400. However, next week could be a big week for the company. The stock's valuation hinges not on electric vehicles (EVs), but its potential leadership in the autonomous driving space. As such, Tesla's upcoming robotaxi launch in Austin, Texas, set for 12 June, has reignited debate over the company's sky-high valuation and the potential for dramatic share price swings in the coming week. The move marks Tesla's long-awaited entry into the autonomous ride-hailing market. With rivals like Waymo, Zoox, and Avride already operating in the city's tech-friendly environment, Tesla may be in danger of falling behind. At the heart of any discussion about Tesla — or any stock — is valuation. Tesla's current and forward multiples remain among the highest in the consumer discretionary sector. The company's forward price-to-earnings (P/E) ratio stands at 180.4 times, nearly 1,000% above the sector median of 16.4 times, and even higher than its own five-year average of 115.1 times. The forward price-to-earnings-to-growth (PEG) ratio is 8.6. That's more than four times the sector median — and remember some of these other companies will pay a dividend. This tells us that even with projected earnings growth, the stock is expensive by growth investing standards. Meanwhile the price-to-sales (P/S) and enterprise value-to-EBITDA (earnings before interest, tax, depreciation, and amortisation) ratios tell a similar story. Tesla's forward P/S is 11.31 (sector median is 0.87), while its forward EV-to-EBITDA is 76.58 (sector median: 9.73). These metrics indicate Tesla is valued not just as a carmaker, but as a tech company with enormous anticipated future profits. The market's optimism, or overoptimism, is rooted in the robotaxi story. Tesla aims to dominate in the sector by quickly scaling its robotaxi operations globally. In theory, it's a high-margin business with strong recurring revenues. This would fundamentally alter the company's earnings profile. However, this optimism is highly speculative and contingent on overcoming significant technical, regulatory, and competitive hurdles. And that's why it's so important that Tesla impresses with its launch next week. There's also the Optimus robot. This is Tesla's humanoid robot, which like the robotaxi venture, is built around developments in artificial intelligence (AI). Optimus could also be game changing. Despite the possibilities, Tesla's valuation leaves little margin for error. And this risk is compounded by the competitive landscape in Austin. Waymo, especially, already established a presence, and its technology relies on different approaches — such as lidar and radar — compared to Tesla's camera-based system. And while Elon Musk touts Tesla's approach as more scalable and cost-effective, the company has a history of missing self-imposed deadlines on autonomy, which could test investor patience if the rollout stumbles. Personally, I want to see Tesla do well. I want companies to succeed and push the boundaries of technology. However, I believe Tesla's execution risk is considerable and the valuation hard to justify. That's why I'm watching from the sidelines. The post The Tesla share price could skyrocket next week! appeared first on The Motley Fool UK. More reading 5 Stocks For Trying To Build Wealth After 50 One Top Growth Stock from the Motley Fool James Fox has no position in any of the shares mentioned. The Motley Fool UK has recommended Tesla. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors. Motley Fool UK 2025 Sign in to access your portfolio
Yahoo
an hour ago
- Yahoo
RBC Capital Reiterated an Outperform Rating on Lyft (LYFT), Assigning a $21 PT
On June 5, RBC Capital analysts maintained an Outperform rating on Lyft, Inc. (NASDAQ:LYFT) with a price target of $21. The analysts mentioned the current rationality in the ride-sharing space, observing identical pricing and pick-up windows for Lyft and Uber, its market rival. Lyft's revenue has demonstrated solid growth over the last year, coming in at 27%. A ridesharing passenger and driver in a car, looking out the window in anticipation of their destination. RBC reported that Lyft, Inc. (NASDAQ:LYFT) is a sector winner year-to-date, ranking fifth overall with an 18% increase, compared to the 1% boost in the Nasdaq. According to the analysts, this performance was driven by Lyft's limited tariff exposure and GenAI concerns, combined with strong execution. Another positive development commended by RBC was Lyft, Inc. (NASDAQ:LYFT)'s autonomous vehicle launch with May Mobility, which is on the horizon. However, the soon-to-be Tesla launch is a potential competitive risk, though analysts commented that a stock selloff related to Tesla was a buying opportunity. The analysts also highlighted Lyft's promising valuation at 7.3x its forecasted 2026 EBITDA. This valuation, paired with the company's tactical plans, was a factor that contributed to RBC's Outperform rating. Lyft, Inc. (NASDAQ:LYFT) is a leading peer-to-peer transportation company operating across the United States and Canada, offering ridesharing, shared bikes/scooters, and Express Drive rentals. While we acknowledge the potential of LYFT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock. READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money. Disclosure: None. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
2 hours ago
How major US stock indexes fared Friday, 6/6/2025
Stocks rose on Wall Street following a better-than-expected report on the U.S. job market. The S&P 500 climbed 1% Friday, marking its second weekly gain in a row. The Dow Jones Industrial Average added 1%, and the Nasdaq composite rose 1.2%. U.S. employers slowed their hiring last month, but still added a solid 139,000 jobs amid uncertainty over President Donald Trump's trade wars. Lululemon Athletica sank after lowering its profit forecast for the full year. On Friday: The S&P 500 rose 61.06 points, or 1%, to 6,000.36. The Dow Jones Industrial Average rose 443.13 points, or 1%, to 42,762.87. The Nasdaq composite rose 231.50 points, or 1.2%, to 19,529.95. The Russell 2000 index of smaller companies rose 34.89 points, or 1.7%, to 2,132.25. For the week: The S&P 500 is up 88.67 points, or 1.5%. The Dow is up 492.80 points, or 1.2%. The Nasdaq is up 416.19 points, or 2.2%. The Russell 2000 is up 65.96 points, or 3.2%. For the year: The S&P 500 is up 118.73 points, or 2%. The Dow is up 218.65 points, or 0.5%. The Nasdaq is up 219.16 points, or 1.1%. The Russell 2000 is down 97.91 points, or 4.4%.
